CALCIUM POLYCARBOPHIL

N/A

Manufactured by Aurobindo Pharma Limited

6,699 FDA adverse event reports analyzed

Last updated: 2026-04-15

About CALCIUM POLYCARBOPHIL

CALCIUM POLYCARBOPHIL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for CALCIUM POLYCARBOPHIL include FATIGUE, DIARRHOEA, CONSTIPATION, FALL, PAIN. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CALCIUM POLYCARBOPHIL.

Top Adverse Reactions

FATIGUE226 reports
DIARRHOEA212 reports
CONSTIPATION203 reports
FALL197 reports
PAIN189 reports
NAUSEA184 reports
DYSPNOEA155 reports
HEADACHE150 reports
DRUG INEFFECTIVE141 reports
OFF LABEL USE135 reports
DIZZINESS130 reports
ASTHENIA121 reports
DEATH109 reports
HYPOTENSION109 reports
WEIGHT DECREASED105 reports
BALANCE DISORDER100 reports
URINARY TRACT INFECTION89 reports
VOMITING87 reports
PNEUMONIA86 reports
COGNITIVE DISORDER84 reports
ARTHRALGIA81 reports
PYREXIA80 reports
MOBILITY DECREASED79 reports
ABDOMINAL PAIN74 reports
RASH74 reports
PRURITUS73 reports
ANXIETY71 reports
COUGH71 reports
INSOMNIA71 reports
MALAISE71 reports
SEDATION71 reports
DECREASED APPETITE70 reports
PAIN IN EXTREMITY70 reports
TOXICITY TO VARIOUS AGENTS70 reports
WEIGHT INCREASED70 reports
FEELING ABNORMAL69 reports
DEPRESSION68 reports
ORTHOSTATIC HYPOTENSION68 reports
BLOOD CALCIUM DECREASED66 reports
DEPRESSED LEVEL OF CONSCIOUSNESS66 reports
CREATININE RENAL CLEARANCE DECREASED65 reports
BACK PAIN64 reports
SEDATION COMPLICATION64 reports
ANAEMIA61 reports
HYPERTENSION61 reports
DRUG INTERACTION56 reports
GAIT DISTURBANCE56 reports
COVID 1955 reports
SINUSITIS55 reports
PRODUCT USE IN UNAPPROVED INDICATION54 reports
CHEST PAIN53 reports
OEDEMA PERIPHERAL53 reports
CONDITION AGGRAVATED52 reports
MUSCLE SPASMS51 reports
MYALGIA49 reports
ABDOMINAL DISTENSION48 reports
ABDOMINAL PAIN UPPER48 reports
PRODUCT DOSE OMISSION ISSUE48 reports
SOMNOLENCE47 reports
NASOPHARYNGITIS45 reports
BLOOD PRESSURE INCREASED44 reports
DEHYDRATION43 reports
MEMORY IMPAIRMENT43 reports
ATRIAL FIBRILLATION42 reports
HYPOAESTHESIA41 reports
INJECTION SITE PAIN41 reports
ALOPECIA40 reports
INFECTION39 reports
NEUROPATHY PERIPHERAL39 reports
PARAESTHESIA39 reports
VISION BLURRED39 reports
DRUG HYPERSENSITIVITY38 reports
CONFUSIONAL STATE37 reports
TREMOR36 reports
BRONCHITIS35 reports
DYSPEPSIA35 reports
MUSCULAR WEAKNESS35 reports
RENAL FAILURE35 reports
GASTROOESOPHAGEAL REFLUX DISEASE34 reports
HOT FLUSH34 reports
ABDOMINAL DISCOMFORT33 reports
OVERDOSE33 reports
CELLULITIS32 reports
CEREBROVASCULAR ACCIDENT32 reports
ACUTE KIDNEY INJURY31 reports
PALPITATIONS31 reports
PRODUCT USE ISSUE31 reports
RENAL FUNCTION TEST ABNORMAL31 reports
DRUG DOSE OMISSION30 reports
ILLNESS30 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION30 reports
CHRONIC KIDNEY DISEASE29 reports
CONTUSION29 reports
DYSPHAGIA29 reports
HOSPITALISATION29 reports
PERIPHERAL SWELLING29 reports
FLUSHING28 reports
HYPERSENSITIVITY28 reports
URTICARIA28 reports
ERYTHEMA27 reports

Report Outcomes

Out of 2,863 classified reports for CALCIUM POLYCARBOPHIL:

Serious 62.7%Non-Serious 37.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female1,747 (64.0%)
Male979 (35.9%)
Unknown2 (0.1%)

Reports by Age

Age 77110 reports
Age 7359 reports
Age 7558 reports
Age 7457 reports
Age 6254 reports
Age 6854 reports
Age 6549 reports
Age 7149 reports
Age 6147 reports
Age 7646 reports
Age 6945 reports
Age 7045 reports
Age 7843 reports
Age 6742 reports
Age 6641 reports
Age 5740 reports
Age 7940 reports
Age 6039 reports
Age 5438 reports
Age 8138 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CALCIUM POLYCARBOPHIL?

This profile reflects 6,699 FDA FAERS reports that mention CALCIUM POLYCARBOPHIL. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CALCIUM POLYCARBOPHIL?

Frequently reported terms in FAERS include FATIGUE, DIARRHOEA, CONSTIPATION, FALL, PAIN, NAUSEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CALCIUM POLYCARBOPHIL?

Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with CALCIUM POLYCARBOPHIL. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.